Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Radiotherapy | Research

A nomogram predicting overall survival in patients with non-metastatic pancreatic head adenocarcinoma after surgery: a population-based study

Authors: Wenbo Zou, Zizheng Wang, Fei Wang, Gong Zhang, Rong Liu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Pancreatic head adenocarcinoma (PHAC), a malignant tumour, has a very poor prognosis, and the existing prognostic tools lack good predictive power. This study aimed to develop a better nomogram to predict overall survival after resection of non-metastatic PHAC.

Methods

Patients with non-metastatic PHAC were collected from the Surveillance, Epidemiology, and End Results (SEER) database and divided randomly into training and validation cohorts at a ratio of 7:3. Cox regression analysis was used to screen prognostic factors and construct the nomogram. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated to evaluate the performance of the model. The predictive accuracy and clinical benefits of the nomogram were validated using the area under the curve (AUC), calibration curves, and decision curve analysis (DCA).

Results

From 2010 to 2016, 6419 patients with non-metastatic PHAC who underwent surgery were collected from the SEER database. A model including T stage, N stage, grade, radiotherapy, and chemotherapy was constructed. The concordance index of the nomogram was 0.676, and the AUCs of the model assessing survival at multiple timepoints within 60 months were significantly higher than those of the American Joint Committee on Cancer (AJCC) 8th staging system in the training cohort. Calibration curves showed that the nomogram had ability to predict the actual survival. The NRI, IDI, and DCA curves also indicated that our nomogram had higher predictive capability and clinical utility than the AJCC staging system.

Conclusions

Our nomogram has an ability to predict overall survival after resection of non-metastatic PHAC and includes prognostic factors that are easy to obtain in clinical practice. It would help assist clinicians to conduct personalized medicine.

Available only for authorised users

Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–20. https://doi.org/10.1016/S0140-6736(20)30974-0.CrossRefPubMed

Zhu H, Li T, du Y, Li M. Pancreatic cancer: challenges and opportunities. BMC Med. 2018;16(1):214. https://doi.org/10.1186/s12916-018-1215-3.CrossRefPubMedPubMedCentral

Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. Therapeutic developments in pancreatic cancer: current and future perspectives. Nat Rev Gastroenterol Hepatol. 2018;15(6):333–48. https://doi.org/10.1038/s41575-018-0005-x.CrossRefPubMed

McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846–61. https://doi.org/10.3748/wjg.v24.i43.4846.CrossRefPubMedPubMedCentral

Seufferlein T, Hammel P, Delpero JR, Macarulla T, Pfeiffer P, Prager GW, et al. Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: expert opinion based on a review of current evidence. Cancer Treat Rev. 2019;77:1–10. https://doi.org/10.1016/j.ctrv.2019.05.007.CrossRefPubMed

Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163–72. https://doi.org/10.1038/nrclinonc.2009.236.CrossRefPubMed

Lou X, Li J, Wei YQ, Jiang ZJ, Chen M, Sun JJ. Comparable prevalence of distant metastasis and survival of different primary site for LN + pancreatic tumor. J Transl Med. 2020;18(1):266. https://doi.org/10.1186/s12967-020-02438-1.CrossRefPubMedPubMedCentral

MB A, American joint committee on Cancer, American Cancer Society. AJCC Cancer staging manual. In: American Joint Committee on Cancer. 8th ed. Chicago: Springer; 2017.

Sheng W, Dong M, Wang G, Shi X, Gao W, Wang K, et al. The diversity between curatively resected pancreatic head and body-tail cancers based on the 8th edition of AJCC staging system: a multicenter cohort study. BMC Cancer. 2019;19(1):981. https://doi.org/10.1186/s12885-019-6178-z.CrossRefPubMedPubMedCentral

10.

Zou Y, Han H, Ruan S, Jian Z, Jin L, Zhang Y, et al. Development of a Nomogram to predict disease-specific survival for patients after resection of a non-metastatic adenocarcinoma of the pancreatic body and tail. Front Oncol. 2020;10:526602. https://doi.org/10.3389/fonc.2020.526602.CrossRefPubMedPubMedCentral

11.

He C, Sun S, Zhang Y, Lin X, Li S. Score for the overall survival probability of patients with pancreatic adenocarcinoma of the body and tail after surgery: a novel Nomogram-based risk assessment. Front Oncol. 2020;10:590. https://doi.org/10.3389/fonc.2020.00590.CrossRefPubMedPubMedCentral

12.

Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: a review. Cancer Lett. 2016;381(1):269–77. https://doi.org/10.1016/j.canlet.2016.07.022.CrossRefPubMed

13.

Okada K, Murakami Y, Kondo N, Uemura K, Nakagawa N, Seo S, et al. Prognostic significance of lymph node metastasis and micrometastasis along the left side of superior mesenteric artery in pancreatic head Cancer. J Gastrointest Surg. 2019;23(10):2100–9. https://doi.org/10.1007/s11605-019-04359-x.CrossRef

14.

Tsai S, George B, Wittmann D, Ritch PS, Krepline AN, Aldakkak M, et al. Importance of normalization of CA19-9 levels following Neoadjuvant therapy in patients with localized pancreatic Cancer. Ann Surg. 2020;271(4):740–7. https://doi.org/10.1097/SLA.0000000000003049.CrossRefPubMed

15.

You MS, Lee SH, Choi YH, Shin BS, Paik WH, Ryu JK, et al. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment. BMC Cancer. 2019;19(1):952. https://doi.org/10.1186/s12885-019-6193-0.CrossRefPubMedPubMedCentral

16.

Tol JA, et al. Impact of lymph node ratio on survival in patients with pancreatic and periampullary cancer. Br J Surg. 2015;102(3):237–45. https://doi.org/10.1002/bjs.9709.CrossRefPubMed

17.

Hartwig W, Hackert T, Hinz U, Gluth A, Bergmann F, Strobel O, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011;254(2):311–9. https://doi.org/10.1097/SLA.0b013e31821fd334.CrossRefPubMed

18.

Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg. 2004;70(3):235–40 discussion 240.PubMed

19.

Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. Preoperative Chemoradiotherapy versus immediate surgery for Resectable and borderline Resectable pancreatic Cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73. https://doi.org/10.1200/JCO.19.02274.CrossRefPubMed

20.

Liu JH, Wang SF, Li BR, Zhu X. Development and validation of an individualized nomogram for predicting pancreatic adenocarcinoma-specific survival: a SEER population analysis of 5,805 patients. Eur Rev Med Pharmacol Sci. 2020;24(20):10483–95. https://doi.org/10.26355/eurrev_202010_23401.CrossRefPubMed

21.

Krishnan S, Chadha AS, Suh Y, Chen HC, Rao A, Das P, et al. Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic Cancer patients receiving induction chemotherapy and consolidative Chemoradiation. Int J Radiat Oncol Biol Phys. 2016;94(4):755–65. https://doi.org/10.1016/j.ijrobp.2015.12.003.CrossRefPubMed

22.

Mas L, Schwarz L, Bachet JB. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. Curr Opin Oncol. 2020;32(4):356–63. https://doi.org/10.1097/CCO.0000000000000639.CrossRefPubMed

Title: A nomogram predicting overall survival in patients with non-metastatic pancreatic head adenocarcinoma after surgery: a population-based study
Authors: Wenbo Zou
Zizheng Wang
Fei Wang
Gong Zhang
Rong Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Radiotherapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08250-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety

Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer

MicroRNA-545 suppresses progression of ovarian cancer through mediating PLK1 expression by a direct binding and an indirect regulation involving KDM4B-mediated demethylation

Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells

Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study

Association of dietary intakes of vitamin B12, vitamin B6, folate, and methionine with the risk of esophageal cancer: the Japan Public Health Center-based (JPHC) prospective study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer